

**What is claimed is**:

1. Use of a compound of formula I (Compound I)



(I),

or a compound of formula II (Compound II)



(II),

or a pharmaceutically acceptable salt, hydrate, or solvate of Compound I or Compound II, in the manufacture of a medicament for treating at least one symptom of an anxiety disorder in a human subject who is diagnosed with Major Depressive Disorder (MDD), wherein the medicament is to be orally administered to the subject, wherein the medicament comprises a therapeutically effective amount of the composition, and wherein the therapeutically effective amount is a total daily dose of Compound I or Compound II of 0.5 mg to 2.5 mg.

2. The use according to claim 1, wherein the therapeutically effective amount is a total daily dose of 0.5 mg of Compound I or Compound II.

3. The use according to claim 1 or 2, wherein the human subject has been diagnosed with moderate to severe MDD.

4. The use according to any one of claims 1 to 3, wherein Compound I or Compound II is to be administered for a treatment period selected from the group consisting of at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks and at least 6 weeks.